Weight Loss Drug News

Jun 15, 2007 09:49

An FDA advisory panel announced yesterday that they voted unanimously against the approval of a new weight loss drug, rimonabant (planned to be marketed in the US under the brand name Zimulti). The panel stated that the applicant drug manufacturer, French-based sanofi-aventis, did not show sufficient safety of the drug. Specifically, subjects ( Read more... )

drug information

Leave a comment

Comments 5

whataruckus June 15 2007, 17:25:55 UTC
OMG... that was just plain odd... I read that and when I got to the last paragraph, all I heard was the commercial-man's voice reading very quickly...

Reply


tonymorg June 15 2007, 17:30:36 UTC
Oily anal leakage?

Oily anal leakage?

I'm sure there's a joke in there somewhere, but I just can't find it quickly.

:o)

Happy Friday.

Reply


(The comment has been removed)

moofedct June 15 2007, 20:49:38 UTC
I'm 5'9 and 160. I'd buy it. But then I'm a little messed up in the head.

Reply


moofedct June 15 2007, 20:53:55 UTC
FDA is not required to follow the recommendation of the advisory panel

You got that right. The CRAC (cardio-renal advisory committee) that judged Natrecor (Nesiritide) for Scios back in 1998 recommended against its approval and so it was not approved. A few years ago, it received unanimous approval by the committee and FDA later approved it.

Reply


kingfuraday June 15 2007, 22:06:24 UTC
As much as I love some good anal leakage I think I'll stick with trying the whole eat less, exercise more thing.

Reply


Leave a comment

Up